Subscribe To

Price Alert Latest News Economic Calendar News

ENOV / Enovis Corporation (ENOV) CEO Matt Trerotola on Q2 2022 Results - Earnings Call Transcript

Enovis Corporation (NYSE:ENOV ) Q2 2022 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Derek Leckow - Vice President, Investor Relations Matt Trerotola - Chief Executive Officer Chris Hix - Executive Vice President & Chief Financial Officer Ben Berry - Interim Chief Financial Officer Conference Call Participants Jeff Johnson - Baird Vik Chopra - Wells Fargo Matthew Mishan - KeyBanc Jason Wittes - Loop Capital Operator Ladies and gentlemen, thank you for standing by, and welcome to the Enovis Second Quarter 2022 Earnings Call. All lines have been placed on mute to prevent any background noise. Read More

Demo Live Account See Partner Details

Content Topics

Enovis

Corporation

ENOV

Matt

Trerotola

2022

Results

enov

Earnings

Transcript

Stock

Posted: Aug 6 2022, 13:04

Author Name: Seeking Alpha

ENOV News

By Zacks Investment Research
October 31, 2023

Enovis (ENOV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Enovis (ENOV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key

By Zacks Investment Research
October 25, 2023

Will Enovis (ENOV) Beat Estimates Again in Its Next Earnings Report?

Enovis (ENOV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat i

By Zacks Investment Research
September 29, 2023

Bear Of The Day: Enovis (ENOV)

Enovis (ENOV) is a Zacks Rank #5 (Strong Sell) has seen earnings estimates slide lower recently despite a good history of beating Zacks Consensus Esti

By Market Watch
September 25, 2023

Enovis to acquire implant maker LimaCorporate for 800 million euros in cash and stock

Medical technology company Enovis Corp. ENOV, -0.44% said Monday it has reached an agreement to acquire LimaCorporate S.p.A., a privately held orthope

By GlobeNewsWire
August 8, 2023

Enovis to Participate in Upcoming Investor Conferences

Wilmington, DE, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today a

By Seeking Alpha
August 6, 2023

Enovis Corporation (ENOV) Q2 2023 Earnings Call Transcript

Enovis Corporation (NYSE:ENOV ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Derek Leckow - Vice President of Inves

By Seeking Alpha
July 18, 2023

Enovis Corporation: Things Are Looking Good As Guidance Is Raised

Enovis Corporation continues to grow, with revenues increasing by 16% in the Recon part of their business, and the company's share price also growing

By GlobeNewsWire
July 11, 2023

Enovis to Host Second Quarter 2023 Results Conference Call on August 3rd

Wilmington, DE, July 11, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today a

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.